BRAF and non-small cell lung carcinoma: This case provides supporting evidence for the perioperative application of BRAF inhibitors and MEK inhibitors in patients with stage IIIA BRAF V600E NSCLC, which can improve the prognosis of locally advanced BRAF V600E NSCLC.